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Despite enormous difficulties to induce antibodies neutralizing HIV-1, especially broadly neutralizing antibodies
directed against the conserved membrane proximal external region (MPER) of the transmembrane envelope
protein, such antibodies can be easily induced in the case of gammaretroviruses, among them the porcine
endogenous retroviruses (PERVs). In addition to neutralizing antibodies directed against the transmembrane
envelope protein p15E, neutralizing antibodies were also induced by immunization with the surface envelope
protein gp70. PERVs represent a special risk for xenotransplantation using pig tissues or organs since they are
integrated in the genome of all pigs and infect human cells and a vaccine may protect from transmission to the
recipient. To investigate the effect of simultaneous immunization with both proteins in detail, a study was
performed in hamsters. Gp70 and p15E of PERV were produced in E. coli, purified and used for immunization. All
animals developed binding antibodies against the antigens used for immunization. Sera from animals immunized
with p15E recognized epitopes in the MPER and the fusion peptide proximal region (FPPR) of p15E. One MPER
epitope showed a sequence homology to an epitope in the MPER of gp41 of HIV-1 recognized by broadly
neutralizing antibodies found in HIV infected individuals. Neutralizing antibodies were detected in all sera. Most
importantly, sera from animals immunized with gp70 had a higher neutralizing activity when compared with the
sera from animals immunized with p15E and sera from animals immunized with gp70 together with p15E had a
higher neutralizing activity compared with sera from animals immunized with each antigen alone. These
immunization studies are important for the development of vaccines against other retroviruses including the
human immunodeficiency virus HIV-1.
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A vaccine is the best protection from an infection with
retroviruses including the human immunodeficiency
virus HIV-1. Since retroviruses integrate a DNA copy of
their genome into the genome of the target cell, were
they may persist undetected from the immune system if
not expressed, only vaccines based on neutralizing anti-
bodies can prevent virus infection and integration. Neu-
tralizing antibodies have been found in HIV-1 infected
individuals, most of them are directed against the sur-
face envelope protein gp120, and only some against the
transmembrane envelope protein [1,2]. Two monoclonal* Correspondence: DennerJ@rki.de
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reproduction in any medium, provided the orantibodies binding to a highly conserved domain in the
membrane proximal external region (MPER) of gp41,
designated 2F5 and 4E10, have been shown to neutralize
up 95% of HIV, however, all attempts to induce such
broadly neutralizing antibodies failed until now (for review
see [3]). In contrast to HIV-1 it seems easy to induce
MPER-specific neutralizing antibodies against gammare-
troviruses such as the porcine endogenous retroviruses
(PERVs), the feline leukemia virus (FeLV), and the Koala
retrovirus, KoRV [4-9].
PERVs pose a special risk when xenotransplantation
using pig cells, tissues or organs will be performed in
order to overcome the shortage of human allotrans-
plants [10]. PERVs are present in the genome of all pigs,
can be released by normal pig cells and infect humanLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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clinical and clinical xenotransplantations as well as in in-
fection experiments, no transmission of PERV was
observed, additional safety strategies are under consider-
ation among them vaccination of the human recipient
[11]. We recently reported neutralizing antibodies after
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Figure 1 Antigens, immunization schedule and analysis of the immun
antigens used for immunization. (a) Precursor envelope protein of PERV-A (
sites (PCS) are marked with arrow heads, SP - signal peptide. R - R peptide.
N-terminal pelB leader sequence promoting translocation to the periplasm
fused calmodulin binding protein (CBP) as expressed using the vector pCal
and bleedings. (C) SDS-PAGE of the purified p15E (12 kDa) and (D) gp70 (5
and gp70 (D) used for immunization. The fragile gp70 showed smaller mo
lane 2 – purified p15E (C) or gp70 (D), lane 3–7, sera from animals immuni
animals immunized with gp70, lane 12–15, sera from animals immunized w
with adjuvant.p15E of PERV in goats [4] and rats [12]. The sera recog-
nized epitopes in the fusion peptide proximal region
(FPPR) and the MPER of p15E. When immunizing with
the surface envelope protein gp70 much higher titers of
neutralizing antibodies were induced compared with
p15E [12]. Since studies in rats were hampered by the
high prevalence of preexisting antibodies against p15E,ALYSIS
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e sera. (A) Schematic presentation of the viral envelope proteins and
numbering according accession number AJ133817), protease cleavage
(b) Recombinant gp70 as expressed using vector pET22b(+) with an
a and a C-terminal His-tag. (c) Recombinant p15E with N-terminal
-n. (B) Immunization schedule indicating the time of immunization
4 kDa) and Western blot analyses of the immune sera using p15 (C)
lecules due to proteolysis. Lane 1 – marker proteins (not shown in D),
zed with p15E, one serum was tested twice, lane 8–9, sera from




























































Figure 2 ELISA of the sera from immunized animals. (A, B)
Titration of the sera from animals immunized with p15E, gp70, p15E
and gp70 and control animals using recombinant p15E (A) and
gp70 (B) as antigen. The median of all four animals and the
corresponding standard deviations are shown. (C) Kinetics of
induction of antibodies binding to p15E in animals immunized with
p15E or p15E and gp70. The dilution of the serum was 1:200. At day
62 and 90 the difference is significant (p=0.028).
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p15E were immunized and the effect of simultaneous
immunization with p15E and gp70 was analyzed. Im-
munizing hamsters with p15E resulted in neutralizing
antibodies showing a similar epitope pattern as described
when immunizing other species. Immunizing hamsters
with gp70 also induced higher levels of neutralizing anti-
bodies when compared with the immunization with p15E
and immunizing with both envelope proteins resulted in
higher titers of neutralizing antibodies compared with the
immunization with one antigen alone.Results
Binding antibodies after immunization with p15E and
gp70 of PERV
In order to induce neutralizing antibodies, the trans-
membrane envelope protein p15E and the surface enve-
lope protein gp70 of PERV (Figure 1A) were expressed
in E. coli, purified (Figure 1B) and hamsters were immu-
nized (Figure 1B). Specific binding antibodies were
found using Western blot analysis and ELISA in all im-
mune sera (Figure 1C, Figure 2). Although the animals
in the group immunized with p15E alone and the ani-
mals immunized with p15E and gp70 together received
identical amounts of p15E, it remains unknown why the
response against p15E is higher in the first group. Inves-
tigations of the kinetics showed that already after the
first immunization relatively high titers of binding anti-
bodies were observed, which gradually increased after
each immunization (Figure 2B).
Analyzes of the epitopes recognized by antibodies
specific for p15E of PERV
In order to map the epitopes in p15E recognized by the
immune sera, two different methods were performed.
First, overlapping peptides corresponding to the entire
p15E were immobilized on a membrane (Figure 3A),
and second, a new method was applied using the same
overlapping peptides but immobilized on a glass chip
(Figure 3B). Both methods identified the same epitopes.
In the case of the serum from animal 1/3 immunized
with p15E alone, the only epitopes were localized in the
MPER of p15E. The localization of the epitopes is simi-
lar to the localization described for epitopes induced by
immunization with p15E in goats and rats [13]. One of
the epitopes in the MPER (GWFEGWFNR) is similar in
localization and sequence with the epitope of the mono-
clonal antibody 4E10 (NWFNIT, identical amino acids
in bold) (Figure 3). 4E10 had been isolated from a HIV-1
infected individual and neutralizes up to 95% of all HIV-
1 [14,15]. Despite this limited sequence homology the
anti-p15E antibodies and 4E10 did not cross-react and
not cross-neutralize (not shown). A screening for bind-
ing antibodies using the peptides E1 and E2 (Figure 3C)
was not succesful, obviously the peptides were too short
to bind the antibodies.
Neutralizing antibodies after immunization with p15E and
gp70 of PERV
To analyze the neutralizing activity of the sera a
neutralization assay based on the measurement of viral
DNA after transcription of the viral genomic RNA by
the reverse transcriptase using a real-time PCR was per-
formed and neutralizing activity was found in all im-
mune sera, but not in the preimmune sera and in the








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3 Epitope mapping of the immune sera using two different methods. (A) Example of an epitope mapping using membranes: serum
from hamster 1/3, immunized with p15E. 15-mer peptides overlapping by 12 residues were fixed on the membrane, stained peptides were
identified and epitopes determined. (B) Example of an epitope mapping using glass slides and the same peptides as in A. Hamster 3/4 was
immunized with p15E and gp70 together. (C) Summary of the epitopes recognized by two immune sera from animals immunized with p15E (1/
1, 1/3) and two sera from animals immunized with p15E and gp70 (3/3, 3/4). The most common epitopes recognized after immunization of
goats, rats, mice, and guinea pigs with p15E [4,12] were framed. The peptides E1 and E2 used for screening of the sera were indicated.
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sera from animals immunized with gp70 when compared
with sera from animals immunized with p15E and the
best neutralization was achieved when both envelope pro-
tein were used simultaneously (Figure 4A, Figure 4B). Tak-
ing both experiments together, the differences were
significant (p=0.004 for the difference p15E and gp70 plus
p15E; p=0.019 for the difference gp70 and gp70 plus
p15E). Investigation of the kinetics showed that the neu-
tralizing activity was still low after two immunizations but
increased significantly after the fourth immunization, indi-
cating that multiple immunizations are required to achieve
a strong neutralization (Figure 4C). Purified IgG from the
immune sera had the same neutralizing effect as the whole
serum, indicating that antibodies are responsible for it.
Discussion
Immunizing for the first time hamsters with the trans-
membrane envelope protein p15E of PERV resulted inneutralizing antibodies recognizing epitopes in the
MPER. These data show that immunization with p15E
in all species tested so far resulted in neutralizing anti-
bodies and in antibodies recognizing similar epitopes
[4,12]. Neutralizing antibodies and antibodies recogniz-
ing the MPER and FPPR had been also induced immun-
izing with p15E of the feline leukemia virus (FeLV) [5-8],
and the koala retrovirus (KoRV) [9]. In the case of the
FeLV it was shown that these antibodies protected cats
in vivo from antigenemia [8]. Whereas in the case of
these gammaretroviruses neutralizing antibodies against
the transmembrane envelope protein could be easily
induced, all attempts to obtain antibodies such as 2F5
and 4E10 broadly neutralizing HIV-1 failed [1-3,16]. In
addition, attempts to induce neutralizing antibodies
against HIV-2 [17], the feline foamyvirus (FFV) [18], and
the primate foamy virus (PFV) (our unpublished data)
immunizing with the transmembrane envelope protein
















































p=0.004 (A plus B)
p=0.019 
(A plus B)
Figure 4 Neutralizing activity of pooled sera. (A) Sera from
animals immunized with p15E (white columns), gp70 (gray columns),
p15E and gp70 (dark gray columns) and control animals (black columns)
were pooled and analyzed. The delta ct mean of three experiments and
the corresponding standard deviation are shown. (B) Shown are the
results of a second experiment and the Student´s T-test evaluation of
both experiments. (C) Increase in the neutralization titer analyzing the
pooled sera from 4 animals immunized with gp70 and p15E. 1 –
preimmune serum, 2 –first bleeding 22 days after the first immunization,
3 –bleeding after the second immunization, 4 –bleeding after the third
immunization. 4 – bleeding after the fourth immunization.
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maretroviruses and those of the lenti- and foamyviruses.
The p15Es are not glycosylated whereas the transmem-
brane envelope proteins gp41 of HIV-1, gp36 of HIV-2,
and gp48 of the foamyviruses are all glycosylated.
Whether glycosylation is important for the interaction of
the MPER and the FPPR when the N-terminal helical re-
gion (NHR) and the C-terminal helical region CHR of
the transmembrane envelope proteins of lenti- and foa-
myviruses interact during infection remains unclear.
There is evidence that in the case of HIV-1 MPER and
FPPR are in closed proximity at certain moments of the
infection process [19-21] and that the presence of a pep-
tide corresponding to the FPPR increases the binding of
2F5 to a peptide containing its epitopes [13].
The neutralization assay used is based on real-time
PCR measuring viral DNA in the cells. This assay has
several advantages: First, it uses the property of retro-
viruses to transcribe the viral RNA genome into proviral
DNA by the viral reverse transcriptase and measures
therefore activity of this enzyme. Second, it measures in-
fection, proviral DNA exists only in the cell. Than higher
the ct values then less provirus and then better the neu-
tralizing serum worked. Therefore we suggest that this
assay is robust. We used the same assay to measure in-
fection by HIV-1 [13]. This neutralization assay is very
sensitive and can be used with low-titer viruses such as
PERV. To establish an alternative method, e.g. using an
ELISA for viral proteins the virus titer is not high
enough to quantify virus infection in 96 well plates.
Measuring in parallel GAPDH allows screening of the
cell viability.
Hamsters have been chosen for several reason: First to
analyze the immune response to p15E in a new species,
second to use a larger animal than mice to derive more
serum for analysis, and third, to avoid the presence of
preexisting antibodies against p15E which were observed
for a long time in the preimmune serum of rats used for
immunization. Obviously these preexisting antibodies
were directed against an endogenous rat gammaretro-
virus which is closely related to PERV and we assume
that the antibodies were cross-reacting. The endogenous
retroviruses of the rat are not well studied [22], but a
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viruses and PERV may be expected. Expression of en-
dogenous retroviruses has been described in numerous
species under physiological (e.g., immune responses
[23-26]) or pathological conditions (e.g., in tumors of
animals [27] and man [28]). Since in hamsters no anti-
bodies cross-reacting with PERV proteins were found,
these immunization studies could be performed.
When immunizing with gp70 the neutralizing activity
is much higher compared to an immunization with p15E
alone and immunization with both envelope proteins
induced higher titers of neutralizing antibodies (Figure 4).
The same observation was made when immunizing rats
with the transmembrane envelope protein of FeLV and
gp70 of FeLV [7].
Since there are other strategies under development to
prevent transmission of PERVs during xenotransplantation
such as inhibition of PERV expression by RNA interfer-
ence [29,30], it is unlikely that a vaccine against PERV will
be required. However, immunization with the transmem-
brane envelope proteins of gammaretroviruses may help
to understand the mechanism of neutralization by MPER-
specific antibodies, which is still unclear. The neutralizing
antibodies may prevent interaction with the lipids in the
membrane or – most likely - conformational changes. The
data shows that the MPER is important for the infection
of all retroviruses and antibodies against the MPER pre-
vent a crucial step in the infection process. In addition, the
data suggests that the use of both envelope proteins may
be of advantage despite the fact that the surface envelope
protein gp120 of HIV-1 is – in contrast to that of the gam-
maretroviruses – highly variable. Furthermore, the data
shows that two or more immunizations may be required
to obtain neutralizing antibodies.
Conclusions
The induction of PERV-specific neutralizing antibodies
in different species including hamster suggests that such
antibodies may also be induced in primates including
man. Since MPER-specific antibodies were found to
neutralize HIV-1 and other retroviruses, these studies
may be useful to understand the mechanism how these







PERV-gag-probe FAM-AGAAGGGACCTTGGCAGACTTTCT-specific broadly neutralizing antibodies. This data also
indicate that the MPER is a highly vulnerable target for
the neutralization of retroviruses in general.
Methods
Cloning and purification of antigens p15E and gp70
The ectodomain of p15E of PERV-A (amino acids 488–
596, accession number HQ688786) and a recombinant
protein corresponding to gp70 of PERV-A (amino acids
49–487, accession number HQ688785) (Figure 1A) were
cloned into the pET-22b(+) expression vector (Novagen,
San Diego, CA), expressed in E. coli BL21-CodonPlus
(DE3)-RP (Stratagene, Amsterdam), and purified by metal
chelating affinity chromatography using Ni-NTA (Qiagen)
as described [12]. The cloned sequence of gp70 resembles
the sequence of gp70 of FeLV, used as the commercial
“Leucogen” for vaccination of cats containing a small part
of p15E [31]. The p15E (LITGPQQLEKGLSNLHRIVT
EDLQALEKSVSNLEESLTSLSEVVLQNRRGLDLLFLKEG
GLCVALKEECCFYVDHSGAIRDSMSKLRERLEKRHKEK
EAGQGWFEGWFN) is a fusion protein with the calmodu-
lin binding protein (CBP) (MKRRWKKNFIAVSAANRFK
KISSSGALLVPR). It theoretical molecular mass is 16.3
kDa, however it is always detected at 12 kDa (Figure 1C).
The molecular mass of the recombinant gp70 is 54 kDa
(Figure 1D).
Immunization
Hamsters (Charles River) were immunized with 300 μg of
p15E, gp70 or both. In the last case, gp70 and p15E were
immunized in different parts of the body. The proteins
were emulsified in complete Freund’s adjuvant intramus-
cularly and subcutaneously (i.m. 50μl, s.c. 700μl). The con-
trol animals were immunized with adjuvant and PBS. The
immune response was boosted by second and third immu-
nizations using incomplete Freund’s adjuvant (Figure 1B).
IgGs were concentrated using Vivapure Q Mini spin col-
umns (Vivascience). Control animals were immunized
with adjuvant only.
Peptides, Western blot, and ELISA
Peptides E1(484–505) GTAALITGPQQLEKGLSNLHRI
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Luxembourg. Western blot and ELISA were performed
as described before [12] using the recombinant proteins
gp70 and p15E. 0.2 μg/well recombinant proteins were
used for ELISA; sera were diluted 1:200 to 1:25600. A
secondary antibody labeled with HRP was used for ECL
detection. Each serum was titrated and the mean of each
group is shown in Figure 1A, B, C).
Epitope mapping
The entire p15E of PERV (130 amino acids) was
synthesized as a cellulose-adsorbed peptide spot library
of 15-mer peptides overlapping by 12 amino acids or a
glass based chip with the same peptides (JPT Peptide Tech-
nologies, Germany) using standard protocols of the supplier.
Sera were diluted 1:1000 and binding was detected using a
chemiluminescence detection solution (ECL, Amersham
Pharmacia Biotech) or bound antibodies were detected
using a DyLight 649 conjugated AffiniPure goat anti-rat IgG
antibody and read at a wavelength of 635 nm in a GenePix
4000 microarray scanner (Molecular Devices, USA). The
data were analyzed using the GenePix Pro software. Epi-
topes were defined as central amino acids shared by all pep-
tides recognized by the antiserum (see Figure 3A, B).
Neutralization assay
The neutralization assays were performed as described
using virus-containing cell-free supernatants produced by
human embryonic kidney 293 cells infected with PERV/5°
[12]. This virus is a recombinant human-tropic PERV-A/C
repeatedly passaged on human cells which was associated
with increased titers and genetic alterations in its long
terminal repeats (LTR) [32]. 100 μl uninfected 293 cell
(1.5 × 105/ml) were seeded in 96 well plates and incubated
for 4 h at 37°C in 5% (v/v) CO2. Sera were decomplemen-
ted by heat inactivation (30 min at 56°C) and 20 μl were
mixed with 80 μl of a PERV dilution, incubated for 30 min
at 37°C and added to the 293 cells. Virus dilutions result-
ing in stable Ct values (25 to 27) were considered as opti-
mal for the neutralization assay. After incubation for 72 h
at 37°C cells were examined by light microscopy for viabil-
ity and the medium was removed. Cells were lysed by
heating at 95°C for 30 min, freezing at −20°C for 6 h, and
incubation with lysis buffer (nuclease free water containing
0.2 mg/ml proteinase K and 10% (v/v) 10×PCR-buffer) at
60°C for at least 3 h. Proteinase K was heat inactivated (30
min at 95°C). For quantification of PERV proviral DNA
the primers gag-for and gag-rev located in the gag gene
and a specific PERV-gag probe (Table 1) were used in a
duplex real-time PCR. The reference gene GAPDH was
amplified with the primers GAPDH-for and GAPDH-rev
and quantified using a GAPDH-probe (Table 1). The 22 μl
reaction mixture consisted of 1x PCR buffer with 1.5 mM
MgCl2, 0.5 μM each of dATP, dCTP, dGTP, dTTP, 5 pmolof each primer, 5 pmol of probe, 1.25 U AmpliTaq GoldW
polymerase and 3 μl lysate. The thermal cycling conditions
used were 10 min at 95°C followed by 50 cycles of 1 min
at 95°C, 1 min at 59°C and 30 s at 72°C in a Stratagene
MX4000 machine. Neutralization was defined as reduction
of provirus integration in the presence of immune serum
and calculated as (ct value of PERV - ct value of GAPDH)
in the presence of serum - (ct value of PERV - ct value of
GAPDH) in the absence of serum. The ct values of
GAPDH were identical in all samples, indicating absence
of toxic effects of the sera. In addition the delta delta ct
values were determined as described [33].
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